PRIMARY STUDY

Comprehensive Assessment of Cannabidiol and HU308 in Acute and Chronic Colitis Models: Efficacy, Safety, and Mechanistic Innovations

Key Findings:  In mice, cannabidiol (CBD) and HU308, a synthetic selective CB2 receptor agonist, significantly reduced inflammation, cytokine levels, and myeloperoxidase activity, while also normalizing glucagon-like peptide-1 (GLP-1) levels, and may be promising treatments for ulcerative colitis and other inflammatory and colitis symptoms.